[HTML][HTML] Post-COVID-19 pulmonary fibrosis
A Mohammadi, I Balan, S Yadav, WF Matos… - Cureus, 2022 - ncbi.nlm.nih.gov
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions
worldwide with a high mortality rate due to a lack of definitive treatment. Despite having a …
worldwide with a high mortality rate due to a lack of definitive treatment. Despite having a …
[HTML][HTML] Interstitial lung disease in connective tissue disease: a common lesion with heterogeneous mechanisms and treatment considerations
T Shao, X Shi, S Yang, W Zhang, X Li, J Shu… - Frontiers in …, 2021 - frontiersin.org
Connective tissue disease (CTD) related interstitial lung disease (CTD-ILD) is one of the
leading causes of morbidity and mortality of CTD. Clinically, CTD-ILD is highly heterogenous …
leading causes of morbidity and mortality of CTD. Clinically, CTD-ILD is highly heterogenous …
[HTML][HTML] Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis
N Hirani, AC MacKinnon, L Nicol, P Ford… - European …, 2021 - Eur Respiratory Soc
Galectin (Gal)-3 is a profibrotic β-galactoside-binding lectin that plays a key role in the
pathogenesis of idiopathic pulmonary fibrosis (IPF) and IPF exacerbations. TD139 is a novel …
pathogenesis of idiopathic pulmonary fibrosis (IPF) and IPF exacerbations. TD139 is a novel …
Performance of candidate serum biomarkers for systemic sclerosis–associated interstitial lung disease
M Elhai, AM Hoffmann‐Vold, J Avouac… - Arthritis & …, 2019 - Wiley Online Library
Objective Interstitial lung disease (ILD) in systemic sclerosis (SS c) runs a highly variable
course, and prediction tools are highly desired. The aim of this study was to assess the …
course, and prediction tools are highly desired. The aim of this study was to assess the …
[HTML][HTML] Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype
Biomarkers have the potential to become central to the clinical evaluation and monitoring of
patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype …
patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype …
[HTML][HTML] Molecular biomarkers in idiopathic pulmonary fibrosis: state of the art and future directions
A Stainer, P Faverio, S Busnelli, M Catalano… - International Journal of …, 2021 - mdpi.com
Idiopathic pulmonary fibrosis (IPF), the most lethal form of interstitial pneumonia of unknown
cause, is associated with a specific radiological and histopathological pattern (the so-called …
cause, is associated with a specific radiological and histopathological pattern (the so-called …
Matrix metalloproteinase: An upcoming therapeutic approach for idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a debilitating condition where excess collagen
deposition occurs in the extracellular matrix. At first sight, it is expected that the level of …
deposition occurs in the extracellular matrix. At first sight, it is expected that the level of …
Biomarkers in idiopathic pulmonary fibrosis
F Drakopanagiotakis, L Wujak, M Wygrecka, P Markart - Matrix Biology, 2018 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a chronic, debilitating, fibrotic lung disease leading to
respiratory failure and ultimately to death. Being the prototype of interstitial lung diseases …
respiratory failure and ultimately to death. Being the prototype of interstitial lung diseases …
[HTML][HTML] Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry …
JL Todd, R Vinisko, Y Liu, ML Neely, R Overton… - BMC pulmonary …, 2020 - Springer
Abstract Background Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs
(TIMPs) play important roles in the turnover of extracellular matrix and in the pathogenesis of …
(TIMPs) play important roles in the turnover of extracellular matrix and in the pathogenesis of …
[HTML][HTML] Serum proteomics identifies biomarkers associated with the pathogenesis of idiopathic pulmonary fibrosis
L Wang, M Zhu, Y Li, P Yan, Z Li, X Chen… - Molecular & Cellular …, 2023 - ASBMB
The heterogeneity of idiopathic pulmonary fibrosis (IPF) limits its diagnosis and treatment.
The association between the pathophysiological features and the serum protein signatures …
The association between the pathophysiological features and the serum protein signatures …